IL2 and neuroblastoma: Several immunotherapies have been developed to target GD2 with the most successful being Dinutuximab (a chimeric monoclonal antibody made from a combination of mouse and human DNA), which, when combined with immune stimulants such as interleukin-2 (IL-2), Granulocyte-macrophage colony-stimulating factor (GM-CSF), and cis-retinoic acid (CRA), demonstrates a higher event-free survival rate in patients with HR-NB compared with chemotherapy [44].